<DOC>
	<DOCNO>NCT00058149</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy gemcitabine oxaliplatin use different way stop tumor cell divide stop grow die . Combining one drug give different way may kill tumor cell . It yet know whether gemcitabine effective without oxaliplatin treat pancreatic cancer . PURPOSE : Randomized phase III trial compare effectiveness gemcitabine without oxaliplatin treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Oxaliplatin Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival patient locally advance metastatic pancreatic cancer treat prolonged infusion gemcitabine v without oxaliplatin vs standard infusion gemcitabine . - Compare toxicity regimens patient . - Compare objective response patient treat regimen . - Compare pattern failure progression-free survival patient treat regimen . - Compare report frequency deep vein thrombosis pulmonary embolism among patient treat regimen . - Compare change quality life , include improved symptom control and/or additional side effect patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord ECOG performance status ( 0 1 v 2 ) disease stage ( locally advance vs metastatic ) . Patients randomize 1 3 treatment arm . - Arm I ( standard treatment ) : Patients receive gemcitabine IV 30 minute weekly 7 week follow 1 week rest course 1 . In subsequent course , patient receive gemcitabine IV 30 minute day 1 , 8 , 15 , course repeat every 4 week absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine IV 150 minute day 1 , 8 , 15 . Courses repeat every 4 week absence disease progression unacceptable toxicity . - Arm III : Patients receive gemcitabine IV 100 minute day 1 oxaliplatin IV 120 minute day 2 . Courses repeat every 2 week absence disease progression unacceptable toxicity . Quality life assess baseline 8 16 week . Patients follow 3 year . PROJECTED ACCRUAL : A total 789 patient ( 263 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced metastatic pancreatic adenocarcinoma poorly differentiate carcinoma Ineligible curative resection Measurable and/or nonmeasurable disease Must evidence disease outside prior radiation field OR radiologically confirm progression disease within radiation field completion radiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC ≥ 3,500/mm^3 OR Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 125,000/mm^3 Hepatic Bilirubin &lt; 2.0 mg/dL AST &lt; 3 time upper limit normal ( ULN ) Renal Creatinine ≤ 1.5 time ULN Cardiovascular No uncontrolled cardiac disease Other Not pregnant nursing Negative pregnancy test Negative vaginal ultrasound patient elevate beta human chorionic gonadotropin level Fertile patient must use effective nonhormonal contraception No malignancy within past 5 year except nonmetastatic , nonmelanoma skin cancer , carcinoma situ cervix , cancer cure surgery small field radiotherapy No active uncontrolled infection No active illness would preclude study participation No symptomatic sensory peripheral neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy metastatic disease No prior ( include adjuvant ) gemcitabine oxaliplatin Prior adjuvant chemotherapy allow provided 6 month last dose adjuvant chemotherapy recurrence pancreatic cancer Prior chemotherapy radiosensitizing agent allowed* NOTE : *To primary site Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy primary tumor site recover No prior radiotherapy 25 % functional bone marrow Surgery See Disease Characteristics Prior surgical resection allow Other No concurrent participation supportive care trial Concurrent enrollment protocol ECOGE1Y03 allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>